ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
14 août 2020 07h30 HE
|
ContraFect Corporation
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
17 juin 2020 07h30 HE
|
ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
15 juin 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
26 mai 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
21 mai 2020 22h59 HE
|
ContraFect Corporation
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
20 déc. 2019 08h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Applied Silver Announces Formation of Athlete Advisory Council with the Appointment of Ian Williams, Former San Francisco 49ers Player, as Athletics Ambassador
13 mars 2019 07h00 HE
|
Applied Silver Inc.
HAYWARD, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Applied Silver, Inc. today announced the appointment of Ian Williams, former San Francisco 49ers defensive lineman and NBC Bay Area Sports Analyst...
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
07 févr. 2019 09h18 HE
|
Vystar Corp
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria.Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other...
Vystar Debuts Enhanced RxAir® UV Light Air Purifiers to Fight Flu, Colds & Airborne Germs
28 janv. 2019 09h37 HE
|
Vystar Corp
Features longer-lasting, more effective UV light for more efficient inactivation of viruses and bacteriaRxAir available for medical, business and residentialRxAir now available via Vystar’s medical...
ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference
14 mars 2018 07h00 HE
|
ContraFect Corporation
YONKERS, New York, March 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...